
In a comprehensive study conducted at 28 French medical centers, the VESPER trial compared two chemotherapy regimens for muscle-invasive bladder cancer. The trial involved 493 patients randomly assigned to either dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC). While overall survival at 5 years showed no significant difference between the two groups in the total perioperative setting, neoadjuvant dd-MVAC demonstrated improved outcomes compared to GC. The findings emphasize potential treatment distinctions and their implications for future bladder cancer research and immunotherapy trials.
Like
Save
Share